Document Detail


Synthetic immune signaling.
MedLine Citation:
PMID:  22326912     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
A successful immune response against pathogens requires the activation of different cell types of the immune system. These activation processes are difficult to study by classical biochemical and genetic methods alone. In this review we describe how approaches of synthetic biology, such as rebuilding of minimal functional signaling systems and the design of new molecules acting as signaling switches, can be used to get a deeper insight into the signaling mechanism of immune cells. In particular, the interaction of receptors with signal-transducing elements can be studied in detail with these new methods. In addition, sophisticated synthetic immune receptors are being tested in the clinic for gene therapy against certain cancer types.
Authors:
Wolfgang Wa Schamel; Michael Reth
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-10
Journal Detail:
Title:  Current opinion in biotechnology     Volume:  -     ISSN:  1879-0429     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100492     Medline TA:  Curr Opin Biotechnol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Ltd.
Affiliation:
Center for Biological Signalling Studies BIOSS and Faculty of Biology, University of Freiburg, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Center for Chronic Immunodeficiency CCI, University Clinics, Freiburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthetic 3D multicellular systems for drug development.
Next Document:  Host cell invasion by apicomplexans: what do we know?